Evidence of treatment benefit: is seeing believing or obfuscation by statistics?
The carefully constructed paper by Veugelers et al. 1 could be read by some as evidence for the effectiveness of therapy. Since most of us believe treatment is useful, is this a case of churchgoers seeing that church is good? It is not that he and his colleagues are wrong, it may simply be that they are 'preaching to the converted'. However, as the era of evidence-based medicine gives way to the new rush of comparative effectiveness research, researchers must remain agnostic before evaluating the sermons.
There are many positive aspects from this paper and the careful approach that the authors have taken to methodically compare the two epochs of time (the era before disease modifying therapies (DMTs) versus post-DMT). They understand the limitations of observational research and use a well-characterized cohort supporting its population-based characteristics with few dropouts, etc. They further acknowledge that because of the limitations of observational studies, no one method of analysis is sufficient to prove a causal association and they approach the problem from two related perspectives. In addition, while they do not note this issue, clinical trials are conducted on select populations. We do not know the selection biases that enter into results when we encourage patients to volunteer and obtain their consent. We know that such processes are necessary, but think of yourself: How many trials have you participated in as a subject? Observational studies such as this at least examine the 'real-world' populations to which trial results are presumably applied.
Nevertheless, there are several beasts hiding in the woods of data-based comparative effectiveness research in multiple sclerosis (MS). The first is the nature of the Expanded Disability Status Scale (EDSS) as the continuous outcome measure. It is well known that this measure is at best an ordinal measurement. While averaging of ordinal measures is often criticized from a statistical perspective, that is not the major concern in this situation. Almost 20 years ago using the Disability Status Scale (DSS) Weinshenker et al. 2 published the median staying times in each step of the EDSS from a population based study. These values were: DSS ¼ 1 (2.78 years); DSS ¼ 2 (2.44 years); DSS ¼ 3 (2.17 years); DSS ¼ 4 (2.07); and DSS ¼ 5 (2.06 years). The unequal staying times in each successive DSS level up to DSS ¼ 6 would have several consequences in this analysis. In the post-DMT era this could mix new patients disproportionately with older patients and since the observational period was longer in the pretreatment era, there would be more of these individuals to contribute to the progression results. This could contribute to slowing of the slopes of progression and even to the achievement of benchmarks of disability. The analyses are 'adjusted' for a starting EDSS, but this still makes some assumptions that may not hold.
Another uncertainty arises in the inclusion of the follow-up time for only the first DMT used before switching. One may assume that switching is in reaction to a change in the patient's condition or a particular side effect, eliminating the follow-up period beyond the first DMT by censoring the patient's experience at that point in time may underestimate the progression to benchmark EDSS levels as well as the rate of change in EDSS due to the truncation of the potentially worsening course of the disease within the patient.
The paper examines on average about 2.5 years of treatment history, roughly equivalent to the time on therapy in some of the earlier MS trials and slightly more than present-day trials, which seem to stop at 2 years. Thus, despite some of the concerns noted above about mixing of populations and the validity of endpoint usage, it seems rather plausible that pre-versus post-treatment periods evaluated over similar durations as clinical trials would replicate their results. In fact, the hazard ratios of benefit exceed what is found in all but a few recent trials. These hazard rate reductions have not been seen in trials for Interferons or Copaxone amongst relapsing remitting patients. However, this could stem from within patient comparisons rather than the between patient comparisons in pivotal trials.
While the paper provides more evidence reinforcing the expected benefit of treatment, an equally important point may be the excellent demonstration of the difficulty of performing comparative effectiveness research within observational data. As Veugelers et al. 1 caution about not interpreting comparisons amongst drugs, the results by treatment and even those not receiving treatment potentially show the selection biases that operate via clinicians in decisions to treat and/or not treat, which make direct comparisons between drugs difficult to interpret. Propensity scores have been suggested as a remedy for this, but the many assumptions in its use are rarely verifiable.
In the end, the availability of rich datasets from which to examine potential outcomes is very cost effective and important. These analyses should be undertaken, but require much more careful analyses and thoughtful consideration than examining clinical trial results. 
